

Review Article



Monitored Anesthesia Care for Cardiovascular Interventions

Jong Wook Song , MD, Sarah Soh , MD, PhD, and Jae-Kwang Shim , MD, PhD

Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea



Received: Aug 17, 2019

Accepted: Aug 26, 2019

Correspondence to

Jae-Kwang Shim, MD, PhD

Department of Anaesthesiology and Pain Medicine, Anaesthesia and Pain Research Institute, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine, 50, Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.
E-mail: aneshim@yuhs.ac

Copyright © 2020. The Korean Society of Cardiology

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID iDs

Jong Wook Song

<https://orcid.org/0000-0001-7518-2070>

Sarah Soh

<https://orcid.org/0000-0001-5022-4617>

Jae-Kwang Shim

<https://orcid.org/0000-0001-9093-9692>

Conflict of Interest

The authors have no financial conflicts of interest.

Author Contributions

Conceptualization: Song JW, Soh S, Shim JK;
Supervision: Shim JK; Writing - original draft: Song JW; Writing - review & editing: Soh S, Shim JK.

ABSTRACT

The interventional cardiology is growing and evolving. Many complex procedures are now performed outside the operating room to manage cardiovascular pathologies which had been traditionally treated with cardiac surgery. Appropriate sedation strategy is crucial for improved patient comfort and successful procedure while ensuring safety. Sedation for cardiovascular intervention is frequently challenging, especially in critically-ill, high-risk patients. This review addresses pre-procedure evaluation and preparation of patients, proper monitoring, commonly used sedatives and analgesics, and considerations for specific procedures. Appropriate depth of sedation and analgesia should be balanced with patient, procedural and institutional factors. Understanding of the pharmacology of sedatives/analgesics, vigilant monitoring, ability and proper preparation for management of potential complications may improve outcomes in patients undergoing sedation for cardiovascular procedures.

Keywords: Sedation; Cardiovascular interventions; Monitored anesthesia care

INTRODUCTION

The interventional cardiology is rapidly growing both in number and complexity. As an integral component of cardiologic procedures, the demand for sedation is also increasing. The goal of procedural sedation is minimizing patients' discomfort and ensuring safety. Depending on the depth, sedation provides anxiolysis, progressive impairment of consciousness, amnesia and analgesia. Appropriate sedation enables patients' immobility during the procedure, facilitating successful procedure while reducing the risk of complication by optimizing environment, as well as improved overall patient satisfaction. Achieving this goal is sometimes challenging, especially in case of critically ill, high-risk patients undergoing complex procedures. Adequate pre-procedural evaluation and preparation, understanding pharmacology of sedatives and analgesics, proper monitoring, ability to rescue patients from unintended deep sedation or related adverse events are mandatory to provide safe and satisfactory sedation in cardiovascular intervention.

Table 1. The continuum of sedation

Description	Minimal sedation	Moderate sedation	Deep sedation	General anesthesia
Responsiveness	Normal	Purposeful response to verbal or tactile stimulation	Purposeful response to repeated or painful stimulation	Unarousable with painful stimulation
Interventions for airway patency	Not required	Not required	Occasionally required	Frequently required
Ventilation	Unaffected	Adequate	Occasionally inadequate	Frequently inadequate
Cardiovascular function	Unaffected	Usually maintained	Usually maintained	May be impaired
Patient's perspective	Awake, calm, probably remember everything	Sleepy, might remember things	Asleep, probably remember very little thing	Asleep, mostly do not remember anything

THE DEPTH OF SEDATION

The depth of sedation is a continuum from minimal, moderate, deep sedation to general anesthesia (**Table 1**).¹⁾ Minimal sedation refers a drug-induced anxiolysis during which patients respond normally to verbal stimulation. Moderate sedation, also called as 'conscious' sedation, indicates an impairment of consciousness during which patients are able to respond purposefully to verbal or light tactile stimulation. During deep sedation, patients respond only after repeated or painful stimulation, and assistance to maintain patent airway may be needed. Patients under general anesthesia cannot be aroused even by painful stimulation, airway patency is usually not maintained without assistance, and spontaneous ventilation is often impaired, requiring positive pressure ventilation. In general, moderate (conscious) sedation is ideal for most percutaneous cardiovascular intervention, however, deep sedation may be required for some patients and/or procedures. More importantly, because sedation is a continuum within a wide range of levels of consciousness, transition to a deeper level may be rapid and not always predictable. Thus, the sedation provider should recognize drifting level of sedation through continuous monitoring, and also be able to rescue the patient from the deeper level of sedation and related complications.²⁾

PRE-PROCEDURE PATIENT ASSESSMENT AND PREPARATION

The sedation provider should be aware of any medical conditions or comorbidities that potentially increase the likelihood of complications, by review of previous medical records and interview with the patients or caregivers. These include abnormalities of major organ system, any allergies, obstructive sleep apnea, morbid obesity, history of psychotropic drug use, and previous experience with sedation.³⁾ The physical examination before sedation should be focused on the respiratory and cardiovascular system. The evaluation of airway is particularly important. Compromises in neck mobility and mouth opening, facial anomaly, teeth condition, neck mass, breathing sound should be checked before the administration of sedation.

Pre-sedation fasting requirements are similar with those for general anesthesia.⁴⁾ Patients are allowed to drink clear liquid (water, sugar water, juice without pulp) until 2 hours before sedation. Minimum fasting time for light meal and non-human milk is 6 hours, and fasting 8 h or more is recommended for fatty food or meat. Routine administration

of gastrointestinal stimulants, medications that block gastric acid secretion, antacids or antiemetics are not recommended. These guidelines are mainly based on studies which investigated gastric volume and pH,⁵⁾ and the impact of pre-sedation fasting time on patients' outcome is not obvious.^{6,7)} However, considering that pulmonary aspiration is a rare but frequently fatal complication, and moderate sedation can be converted to deep sedation or general anesthesia during procedure, it is generally recommended to conform the fasting guideline.

PATIENT MONITORING

Most of sedation-related complications are caused by drug-overdose. According to an analysis of the American Society of Anesthesiologists (ASA) Closed Claims database, respiratory depression was responsible for 21% of sedation-related claims, and almost half of these claims were judged as 'preventable' if proper monitoring were applied with vigilance and alarm system.⁸⁾ It is recommended that all patients undergoing procedural sedation is monitored for respiratory function, hemodynamics and the depth of sedation.⁹⁾ In addition to monitoring devices, it should be emphasized that a designated, trained personal for monitoring of the patient is required to attend throughout the procedure.¹⁾

Respiratory and hemodynamic monitoring

Respiratory depression due to an overdose of sedatives is the most common adverse event during sedation.¹⁰⁾ All patients undergoing procedural sedation should be monitored for hypoxemia or desaturation by pulse oximetry.¹¹⁾ Because pulse oximetry measures arterial oxygen saturation, the detection of compromised respiratory activity can be delayed, especially if patients are receiving supplemental oxygen. For early detection of hypoventilation, monitoring exhaled carbon dioxide tension is superior than pulse oximetry.¹²⁾ Early detection enables rapid interventions to relieve respiratory depression, including adjustment of drug dosing and the depth of sedation, patient stimulation, maneuvers for airway patency, assisted ventilation and supplemental oxygen. Indeed, capnography monitoring was demonstrated to reduce respiratory complication and improve patient safety during procedural sedation with benzodiazepines and opioids.¹³⁾ The sedation provider should also observe vigilantly for qualitative clinical signs, such as movement of chest wall, suprasternal, intercostal, and subcostal retraction, gasping for air, and stridor.

For sedation during cardiovascular procedures, non-invasive blood pressure, heart rate and electrocardiography monitoring is recommended. Invasive blood pressure monitoring is occasionally required for the patients with advanced cardiovascular dysfunction.

Monitoring the depth of sedation

The depth of sedation should be monitored throughout the procedure. Patient may be uncomfortable with light sedation, whereas deep sedation has greater impact on cardiopulmonary function. Thus, the margin of safety for deeper level of sedation may be narrow, especially in patients with impaired cardiopulmonary function. The dose of sedatives and analgesics are carefully titrated according to the depth of sedation as most of sedation-related complications are associated with unintended deeper level of sedation. The sedation provider can monitor the depth of sedation by periodical verbal stimulation as well as other clinical signs. However, some clinicians advocate processed, digitalized form of electroencephalogram-derived monitor to monitor the level of consciousness.

The bispectral index (BIS; Aspect Medical Systems, Norwood, MA, USA) is the one of the most popular monitors of processed electroencephalogram. It receives electroencephalogram signal via a single patch sensor attached on the forehead, analyzes and processes the signal into a single number, ranging 0 (isoelectric electroencephalographic activity) to 100. A BIS value between 90 and 100 indicates fully awoken status, a value between 70 and 90 represents light to moderate sedation. A BIS value of 60 to 70 indicates superficial anesthesia, and a value between 40 and 60 is regarded as an appropriate value for general anesthesia. Monitoring with BIS is continuous and more convenient than assessment of clinical signs alone, however, for relatively short procedures, addition of BIS monitoring seems to provide little benefit over conventional assessment of clinical signs. In a study comparing the BIS monitoring with clinical assessment, awareness, propofol requirement, desaturation and need for hemodynamic and respiratory support were all similar between the study groups in patients undergoing bronchoscopy.¹⁴⁾ Moreover, the correlation between the BIS and the assessed sedation level was very weak.¹⁵⁾ In contrast, procedures which take long time or require moderate to deep sedation may benefit from the BIS monitoring.¹⁶⁻¹⁸⁾

COMMONLY USED SEDATIVES AND ANALGESICS

Midazolam

Midazolam is a benzodiazepine with a rapid onset (1 to 5 minutes) and short duration of action (**Table 2**). It is the most commonly used agent for short procedures requiring light to moderate sedation. It confers anxiolysis and anterograde amnesia. Because it has no analgesic property, it is usually used in combination with opioids. It blunts central respiratory drive response to hypercapnia or hypoxia.¹⁹⁾ The respiratory depressant effect is dose-dependent and might be increased with rapid intravenous bolus administration. A reduced dose is recommended for old age and patients with impaired cardiopulmonary function. Midazolam is thought to have minimal effect in terms of hemodynamic deterioration.²⁰⁾ Midazolam has negligible direct myocardial depressive effect and modest decrease in blood pressure can occur due to mild vasodilation and sympatholytic effect. However, both respiratory and cardiovascular effects are synergistic when midazolam is used in combination of other sedatives and analgesics, for example opioids, leading to severe respiratory depression and hypotension greater than expected by the effect of each drug.²¹⁾ Midazolam is metabolized in liver, and the main metabolite, which possesses sedative activity, is rapidly cleared via kidney. Thus, in patients with liver cirrhosis or renal impairment, midazolam administration can result in profound sedation for longer duration.²²⁾²³⁾

Midazolam may induce agitation, restlessness, aggressiveness or hallucinations.²⁴⁾ This paradoxical disinhibitory reactions develop within several minutes after intravenous administration following transient sedation. It is reported to occur in <1% of midazolam administrations and thought to be associated with loss of cortical resistance and reduced serotonin control.²⁵⁾ Patient with alcohol abuse or psychologic disturbances are at increased risk of paradoxical reactions. The paradoxical reactions may be attenuated with flumazenil or haloperidol.²⁶⁾²⁷⁾

Propofol

Propofol is a sedative-hypnotic agent with no analgesic effect. It has rapid onset (<1 minute) and relatively short context-sensitive half-time, which enables smooth and quick recovery even after prolonged continuous infusion (**Table 2**). Propofol has little paradoxical excitatory effect and low incidence of nausea and vomiting.²⁸⁾ These favorable pharmacokinetic and

pharmacodynamics profile made it one of the most popular intravenous agents in modern anesthetic practice.

The pharmacokinetic model of propofol is described as a 3-compartmental model which consists of central, peripheral (lean tissues) and deep (fat tissues) compartment.²⁹⁾ Following intravenous bolus administration, propofol is rapidly redistributed to a peripheral compartment, resulting in fast offset of its clinical effect (5–10 minutes). Because propofol is lipophilic, the fat compartment acts as a reservoir after prolonged infusion. Redistribution from the fat compartment may delay the offset of action especially in obese patient.³⁰⁾ Time required for decrease in plasma concentrations are also significantly longer in the elderly.²⁹⁾ Nonetheless, recovery after prolonged infusion is relatively quicker compared with other hypnotics such as midazolam, because the rate of metabolism and excretion is faster than the rate of redistribution. The context-sensitive half-time of propofol is 25 minutes after 3 hour-long infusion, whereas midazolam has a context-sensitive half-time of 70 minutes for a similar duration of infusion.³¹⁾ Propofol is mainly metabolized in liver, and the metabolites, which have no hypnotic effect, are excreted via kidney.³⁰⁾

Propofol is a potent respiratory depressant. An intravascular bolus administration may result in apnea. The dose, speed of injection and co-administered drugs, especially opioids, are associated with the incidence and duration of apnea.³²⁾ Propofol infusion at 100 µg/kg/min induces a 40% decrease in tidal volume and a 20% increase in respiratory rate.³³⁾ Propofol also induces cardiovascular depression, with a greater extent compared with other intravascular sedative agents.³⁴⁾ Even in healthy individual with no cardiovascular impairment, propofol produces 25% to 40% decrease in systemic blood pressure. In addition to vasodilatory effect, it also decreases cardiac output and stroke volume. These cardiovascular effects are associated with sympatholytic activity and whether propofol has direct myocardial depressive effect is still controversial.³⁵⁾ Notably, peak hemodynamic effect of propofol tends to follow behind the hypnotic effect.³⁶⁾ So profound hypotension may manifest a few minutes after the patients fall into deeper level of sedation.

The most frequent complaints in patients who receive propofol is pain at injection site, which can be managed with concomitant use of lidocaine at the start of injection.³⁷⁾³⁸⁾ Propofol has no physical dependence, however, it may result in euphoria with sense of 'general well-being', predisposing a risk of addiction or abuse.³⁹⁾ Lipid-based formulation of propofol is susceptible to bacterial contamination and can induce life-threatening sepsis unless stored and handled appropriately in a sterile and aseptic manner.⁴⁰⁾

Dexmedetomidine

Dexmedetomidine is an α -2 adrenergic receptor agonist which has anxiolytic, sedative and analgesic property (Table 2).⁴¹⁾ Compared with clonidine, it is more selective and efficacious.

Table 2. Commonly used sedatives

Sedatives	Dose	Onset	Hypnosis	Analgesia	Side effects
Midazolam	0.01–0.1 mg/kg	1–5 min	++	–	Respiratory depression, paradoxical excitation
Propofol	Bolus: 1–1.5 mg/kg Infusion: 25–100 µg/kg/min	<1 min	++	–	Respiratory depression, hypotension, bradycardia
Dexmedetomidine	1 µg/kg over 10 min followed by infusion at 0.2–0.7 µg/kg/h	10–15 min	+	+	Biphasic hemodynamic effect: hypotension, hypertension, bradycardia
Remifentanyl	0.05–2 µg/kg/min	<1 min	–	++	Respiratory depression, chest wall rigidity, bradycardia, hypotension

It exerts sedative effect by binding to α -2 receptors in the locus coeruleus and analgesic effect by an action on α -2 receptors in spinal cord as well as locus coeruleus.⁴²⁾ Unlike other sedative drugs such as propofol and benzodiazepines, dexmedetomidine induces sedation through the endogenous sleep-promoting pathway.⁴³⁾ Thus, it produces a natural sleep-like patterns of the electroencephalogram, and patients receiving dexmedetomidine usually fall asleep when undisturbed, while they are easily arousable and cooperative. Dexmedetomidine has minimal respiratory depressive effect. Sedation with dexmedetomidine induces modest reduction in minute ventilation,⁴⁴⁾ however, ventilatory response to hypercapnia is unaffected even in deep sedation.⁴⁵⁾ Dexmedetomidine reduces the release of norepinephrine and sympathetic tone in the central nervous system, thus it can induce severe bradycardia.⁴⁶⁾⁴⁷⁾ Transient hypertension can occur due to stimulation of peripheral α -2 receptors. Slow initial loading over 20 minutes may reduce the transient hypertension.⁴⁸⁾ In case of hypertension during initial loading, it is recommended to decrease subsequent continuous infusion rate. Hypotension can also occur, especially in old age, history of diabetes or hypertension, or with a large loading dose. Dexmedetomidine can be used alone or in combination with other sedatives/analgesics. Because dexmedetomidine exerts minimal respiratory depression, combined administration with other sedatives/analgesics provide excellent results without increased risk of respiratory complication.⁴⁹⁾

Opioids

Owing to their strong analgesic efficacy, addition of opioids can ameliorate procedure-related discomfort. Opioids have no hypnotic effect, however, it can reduce the requirements of other hypnotics when used in combination. Because the risk of respiratory and cardiovascular depression increases synergistically with other sedatives, special attention is needed in patients receiving opioids in combination with propofol or midazolam. Remifentanyl is an ultra-short acting synthetic opioid, which has gained popularity recently for conscious sedation during painful procedures.⁵⁰⁾ It has rapid onset and short context-sensitive half time regardless of the duration of infusion. Recovery is rapid even after prolonged infusion and not affected by hepatic or renal function.⁵¹⁾ Initial loading dose is not necessary, and an infusion at 0.05–2 $\mu\text{g}/\text{kg}/\text{min}$ provides sufficient analgesia for most procedures (**Table 2**). However, respiratory depression is not infrequent even at subtherapeutic doses. Like other opioids, remifentanyl infusion occasionally induces chest wall rigidity which impairs ventilation.

CONSIDERATIONS FOR SPECIFIC PROCEDURES

Catheter ablation for arrhythmias

Depending on the complexity of procedures, moderate sedation is feasible for most of cases, either with benzodiazepine, propofol, opioids or dexmedetomidine.⁵²⁻⁵⁴⁾ However, in case of complex procedures, deep sedation or general anesthesia is occasionally required because the procedures can be lengthy and patient immobility is crucial for the induction and accurate mapping of the arrhythmogenic foci. In a trial comparing sedation versus general anesthesia for ablation of atrial fibrillation, general anesthesia was associated with shorter procedure time and higher arrhythmia-free rate.⁵⁵⁾ However, general anesthesia may predispose high incidence of esophageal injury, likely due to reduced esophageal motility and swallowing during general anesthesia.⁵⁶⁾ In addition, absence of feedback from patients might delay the detection of complications during the procedure.

There has been a concern that sedatives/anesthetics have a potential to suppress arrhythmia inducibility, interfering successful ablation of supraventricular tachyarrhythmia. Most of sedatives/anesthetics including volatile anesthetics, propofol, remifentanyl and dexmedetomidine may slow cardiac conduction, exert sympatholytic effect and reduce the ability to elicit arrhythmia, especially in deep sedation with high doses.⁵⁷⁻⁵⁹⁾ A combination of benzodiazepine and fentanyl is thought to have less impact on arrhythmia inducibility.⁶⁰⁾ However, a concrete evidence for superiority of any particular agent in regard to the ability to elicit arrhythmia and impact on success rate of the procedure is lacking so far, thus sedative strategy should be chosen upon a balance of patient comfort, preference and experience of sedation provider, and arrhythmia inducibility.

Electrical cardioversion

Electrical cardioversion is highly stimulating and requires deep sedation to alleviate patient discomfort. However, because the period of stimulation is brief, short-acting agents are recommended for rapid recovery. Either benzodiazepines, opioids, and propofol can be used.⁶¹⁾⁶²⁾ Propofol may have advantage in terms of quick onset and offset of sedation, ease of titration, less nausea and vomiting, whereas it is associated with more frequent episode of apnea and hypotension.⁶³⁾ Despite the theoretical advantage of propofol, benzodiazepines are widely used due to its practitioner familiarity and minimal hemodynamic effects.

Pacemakers and implantable cardiac defibrillators

The insertion of pacemakers and implantable cardiac defibrillators can be performed under minimal to moderate sedation. Tunneling of leads to a subcutaneous pocket needs adequate local anesthesia. Like electrical cardioversion, defibrillation threshold test requires deep sedation. Some patients with advanced heart failure may not be able to tolerate the supine position due to orthopnea and these patients are extremely sensitive to sedatives and opioids. Deep sedation in patients with advanced heart failure frequently results in hemodynamic deterioration due to reduced sympathetic tone. Moreover, retention of carbon dioxide may worsen pulmonary hypertension and lead to right ventricular failure.

Percutaneous transluminal angioplasty

The prevalence of peripheral artery disease and need for an appropriated sedation analgesia for percutaneous transluminal angioplasty is increasing.⁶⁴⁾ Patients undergoing percutaneous transluminal angioplasty are usually old and at increased risk of cardiovascular event. Peripheral artery disease provokes broad spectrums of pain, and ballooning may elicit significant ischemic pain. Thus, adequate pain control is crucial. Opioids alone may provide sufficient analgesia. Combination of opioids such as remifentanyl with benzodiazepines or propofol may improve sedation experience, however, it can increase a risk of respiratory depression.⁶⁵⁾ Addition of dexmedetomidine can confer both sedation and analgesia while sparing the dose of opioids and preserving the respiratory function.⁶⁶⁾

CONCLUSION

Sedation for cardiovascular interventions is frequently challenging. To facilitate successful procedure and improve patients' experience and safety, appropriate depth of sedation and analgesia should be balanced with patient, procedural and institutional factors. Understanding the pharmacology of sedatives/analgesics, ability and proper setting for managing potential

complications, and clear communication between sedation provider and interventionist may improve outcomes in patients undergoing sedation for cardiovascular procedures.

REFERENCES

1. Practice Guidelines for Moderate Procedural Sedation and Analgesia. Practice guidelines for moderate procedural sedation and analgesia 2018: a report by the American Society of Anesthesiologists Task Force on Moderate Procedural Sedation and Analgesia, the American Association of Oral and Maxillofacial Surgeons, American College of Radiology, American Dental Association, American Society of Dentist Anesthesiologists, and Society of Interventional Radiology. *Anesthesiology* 2018;128:437-79.
[PUBMED](#) | [CROSSREF](#)
2. Shabanie A. Conscious sedation for interventional procedures: a practical guide. *Tech Vasc Interv Radiol* 2006;9:84-8.
[PUBMED](#) | [CROSSREF](#)
3. Kang H, Kim DK, Choi YS, Yoo YC, Chung HS. Practice guidelines for propofol sedation by non-anesthesiologists: the Korean Society of Anesthesiologists Task Force recommendations on propofol sedation. *Korean J Anesthesiol* 2016;69:545-54.
[PUBMED](#) | [CROSSREF](#)
4. Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures: an updated report by the American Society of Anesthesiologists Task Force on Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration. *Anesthesiology* 2017;126:376-93.
[PUBMED](#) | [CROSSREF](#)
5. Agarwal A, Chari P, Singh H. Fluid deprivation before operation. The effect of a small drink. *Anaesthesia* 1989;44:632-4.
[PUBMED](#) | [CROSSREF](#)
6. Agrawal D, Manzi SF, Gupta R, Krauss B. Preprocedural fasting state and adverse events in children undergoing procedural sedation and analgesia in a pediatric emergency department. *Ann Emerg Med* 2003;42:636-46.
[PUBMED](#) | [CROSSREF](#)
7. Bell A, Treston G, McNabb C, Monypenny K, Cardwell R. Profiling adverse respiratory events and vomiting when using propofol for emergency department procedural sedation. *Emerg Med Australas* 2007;19:405-10.
[PUBMED](#) | [CROSSREF](#)
8. Bhananker SM, Posner KL, Cheney FW, Caplan RA, Lee LA, Domino KB. Injury and liability associated with monitored anesthesia care: a closed claims analysis. *Anesthesiology* 2006;104:228-34.
[PUBMED](#) | [CROSSREF](#)
9. Sohn HM, Ryu JH. Monitored anesthesia care in and outside the operating room. *Korean J Anesthesiol* 2016;69:319-26.
[PUBMED](#) | [CROSSREF](#)
10. Choi JW, Kim DK, Cho CK, Park SJ, Son YH. Trends in medical disputes involving anesthesia during July 2009–June 2018: an analysis of the Korean Society of Anesthesiologists database. *Korean J Anesthesiol* 2019;72:156-63.
[PUBMED](#) | [CROSSREF](#)
11. Metzner J, Domino KB. Risks of anesthesia or sedation outside the operating room: the role of the anesthesia care provider. *Curr Opin Anaesthesiol* 2010;23:523-31.
[PUBMED](#) | [CROSSREF](#)
12. Cacho G, Pérez-Calle JL, Barbado A, Lledó JL, Ojea R, Fernández-Rodríguez CM. Capnography is superior to pulse oximetry for the detection of respiratory depression during colonoscopy. *Rev Esp Enferm Dig* 2010;102:86-9.
[PUBMED](#) | [CROSSREF](#)
13. Qadeer MA, Vargo JJ, Dumot JA, et al. Capnographic monitoring of respiratory activity improves safety of sedation for endoscopic cholangiopancreatography and ultrasonography. *Gastroenterology* 2009;136:1568-76.
[PUBMED](#) | [CROSSREF](#)
14. Fruchter O, Tirosh M, Carmi U, Rosengarten D, Kramer MR. Prospective randomized trial of bispectral index monitoring of sedation depth during flexible bronchoscopy. *Respiration* 2014;87:388-93.
[PUBMED](#) | [CROSSREF](#)

15. Weaver CS, Hauter WH, Duncan CE, Brizendine EJ, Cordell WH. An assessment of the association of bispectral index with 2 clinical sedation scales for monitoring depth of procedural sedation. *Am J Emerg Med* 2007;25:918-24.
[PUBMED](#) | [CROSSREF](#)
16. Paspatis GA, Chainaki I, Manolaraki MM, et al. Efficacy of bispectral index monitoring as an adjunct to propofol deep sedation for ERCP: a randomized controlled trial. *Endoscopy* 2009;41:1046-51.
[PUBMED](#) | [CROSSREF](#)
17. von Delius S, Salletmaier H, Meining A, et al. Bispectral index monitoring of midazolam and propofol sedation during endoscopic retrograde cholangiopancreatography: a randomized clinical trial (the EndoBIS study). *Endoscopy* 2012;44:258-64.
[PUBMED](#) | [CROSSREF](#)
18. Jung SM, Lee E, Park SJ. Validity of bispectral index monitoring during deep sedation in children with spastic cerebral palsy undergoing injection of botulinum toxin. *Korean J Anesthesiol*. 2019 [Epub ahead of print].
[PUBMED](#) | [CROSSREF](#)
19. Forster A, Gardaz JP, Suter PM, Gemperle M. Respiratory depression by midazolam and diazepam. *Anesthesiology* 1980;53:494-7.
[PUBMED](#) | [CROSSREF](#)
20. Raza SM, Zsigmond EK, Barabas E. Midazolam causes no adverse hemodynamic effects in cardiac patients. *Clin Ther* 1987;10:40-3.
[PUBMED](#)
21. Skarvan K, Schwinn W. Hemodynamic interaction between midazolam and alfentanil in coronary patients. *Anaesthesist* 1986;35:17-23.
[PUBMED](#)
22. Pentikäinen PJ, Väiläsalmi L, Himberg JJ, Crevoisier C. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. *J Clin Pharmacol* 1989;29:272-7.
[PUBMED](#) | [CROSSREF](#)
23. Bauer TM, Ritz R, Haberthür C, et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. *Lancet* 1995;346:145-7.
[PUBMED](#) | [CROSSREF](#)
24. Golparvar M, Saghaei M, Sajedi P, Razavi SS. Paradoxical reaction following intravenous midazolam premedication in pediatric patients - a randomized placebo controlled trial of ketamine for rapid tranquilization. *Paediatr Anaesth* 2004;14:924-30.
[PUBMED](#) | [CROSSREF](#)
25. Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. *Pharmacotherapy* 2004;24:1177-85.
[PUBMED](#) | [CROSSREF](#)
26. Jackson BF, Beck LA, Losek JD. Successful flumazenil reversal of paradoxical reaction to midazolam in a child. *J Emerg Med* 2015;48:e67-72.
[PUBMED](#) | [CROSSREF](#)
27. Khan LC, Lustik SJ. Treatment of a paradoxical reaction to midazolam with haloperidol. *Anesth Analg* 1997;85:213-5.
[PUBMED](#) | [CROSSREF](#)
28. Bryson HM, Fulton BR, Faulds D. Propofol. An update of its use in anaesthesia and conscious sedation. *Drugs* 1995;50:513-59.
[PUBMED](#) | [CROSSREF](#)
29. Schüttler J, Ihmsen H. Population pharmacokinetics of propofol: a multicenter study. *Anesthesiology* 2000;92:727-38.
[PUBMED](#) | [CROSSREF](#)
30. Sahinovic MM, Struys MM, Absalom AR. Clinical pharmacokinetics and pharmacodynamics of propofol. *Clin Pharmacokinet* 2018;57:1539-58.
[PUBMED](#) | [CROSSREF](#)
31. Hughes MA, Glass PS, Jacobs JR. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. *Anesthesiology* 1992;76:334-41.
[PUBMED](#) | [CROSSREF](#)
32. Dahan A, Nieuwenhuijs DJ, Olofsen E. Influence of propofol on the control of breathing. *Adv Exp Med Biol* 2003;523:81-92.
[PUBMED](#) | [CROSSREF](#)
33. Goodman NW, Black AM, Carter JA. Some ventilatory effects of propofol as sole anaesthetic agent. *Br J Anaesth* 1987;59:1497-503.
[PUBMED](#) | [CROSSREF](#)

34. Larsen R, Rathgeber J, Bagdahn A, Lange H, Rieke H. Effects of propofol on cardiovascular dynamics and coronary blood flow in geriatric patients. A comparison with etomidate. *Anaesthesia* 1988;43 Suppl:25-31.
[PUBMED](#) | [CROSSREF](#)
35. Robinson BJ, Ebert TJ, O'Brien TJ, Colinco MD, Muzi M. Mechanisms whereby propofol mediates peripheral vasodilation in humans. Sympathoinhibition or direct vascular relaxation? *Anesthesiology* 1997;86:64-72.
[PUBMED](#) | [CROSSREF](#)
36. Kazama T, Ikeda K, Morita K, et al. Comparison of the effect-site k_{e0} s of propofol for blood pressure and EEG bispectral index in elderly and younger patients. *Anesthesiology* 1999;90:1517-27.
[PUBMED](#) | [CROSSREF](#)
37. Mamiya H, Noma T, Fukuda K, Kasahara M, Ichinohe T, Kaneko Y. Pain following intravenous administration of sedative agents: a comparison of propofol with three benzodiazepines. *Anesth Prog* 1998;45:18-21.
[PUBMED](#)
38. Kim SY, Jeong DW, Jung MW, Kim JM. Reduction of propofol injection pain by utilizing the gate control theory. *Korean J Anesthesiol* 2011;61:288-91.
[PUBMED](#) | [CROSSREF](#)
39. Brechmann T, Maier C, Kaisler M, et al. Propofol sedation during gastrointestinal endoscopy arouses euphoria in a large subset of patients. *United European Gastroenterol J* 2018;6:536-46.
[PUBMED](#) | [CROSSREF](#)
40. Bennett SN, McNeil MM, Bland LA, et al. Postoperative infections traced to contamination of an intravenous anesthetic, propofol. *N Engl J Med* 1995;333:147-54.
[PUBMED](#) | [CROSSREF](#)
41. Lee S. Dexmedetomidine: present and future directions. *Korean J Anesthesiol* 2019;72:323-30.
[PUBMED](#) | [CROSSREF](#)
42. Guo TZ, Jiang JY, Buttermann AE, Maze M. Dexmedetomidine injection into the locus ceruleus produces antinociception. *Anesthesiology* 1996;84:873-81.
[PUBMED](#) | [CROSSREF](#)
43. Angst MS, Ramaswamy B, Davies MF, Maze M. Comparative analgesic and mental effects of increasing plasma concentrations of dexmedetomidine and alfentanil in humans. *Anesthesiology* 2004;101:744-52.
[PUBMED](#) | [CROSSREF](#)
44. Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD. The effects of increasing plasma concentrations of dexmedetomidine in humans. *Anesthesiology* 2000;93:382-94.
[PUBMED](#) | [CROSSREF](#)
45. Hsu YW, Cortinez LI, Robertson KM, et al. Dexmedetomidine pharmacodynamics: part I: crossover comparison of the respiratory effects of dexmedetomidine and remifentanil in healthy volunteers. *Anesthesiology* 2004;101:1066-76.
[PUBMED](#) | [CROSSREF](#)
46. Kang D, Lim C, Shim DJ, et al. The correlation of heart rate between natural sleep and dexmedetomidine sedation. *Korean J Anesthesiol* 2019;72:164-8.
[PUBMED](#) | [CROSSREF](#)
47. Bhana N, Goa KL, McClellan KJ. Dexmedetomidine. *Drugs* 2000;59:263-8.
[PUBMED](#) | [CROSSREF](#)
48. Riker RR, Fraser GL. Adverse events associated with sedatives, analgesics, and other drugs that provide patient comfort in the intensive care unit. *Pharmacotherapy* 2005;25:8S-18S.
[PUBMED](#) | [CROSSREF](#)
49. Giovannitti JA Jr, Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: a review of current clinical applications. *Anesth Prog* 2015;62:31-9.
[PUBMED](#) | [CROSSREF](#)
50. Litman RS. Conscious sedation with remifentanil during painful medical procedures. *J Pain Symptom Manage* 2000;19:468-71.
[PUBMED](#) | [CROSSREF](#)
51. Servin F. Remifentanil; from pharmacological properties to clinical practice. *Adv Exp Med Biol* 2003;523:245-60.
[PUBMED](#) | [CROSSREF](#)
52. Salukhe TV, Willems S, Drewitz I, et al. Propofol sedation administered by cardiologists without assisted ventilation for long cardiac interventions: an assessment of 1000 consecutive patients undergoing atrial fibrillation ablation. *Europace* 2012;14:325-30.
[PUBMED](#) | [CROSSREF](#)

53. Wutzler A, Loehr L, Huemer M, et al. Deep sedation during catheter ablation for atrial fibrillation in elderly patients. *J Interv Card Electrophysiol* 2013;38:115-21.
[PUBMED](#) | [CROSSREF](#)
54. Cho JS, Shim JK, Na S, Park I, Kwak YL. Improved sedation with dexmedetomidine-remifentanyl compared with midazolam-remifentanyl during catheter ablation of atrial fibrillation: a randomized, controlled trial. *Europace* 2014;16:1000-6.
[PUBMED](#) | [CROSSREF](#)
55. Di Biase L, Conti S, Mohanty P, et al. General anesthesia reduces the prevalence of pulmonary vein reconnection during repeat ablation when compared with conscious sedation: results from a randomized study. *Heart Rhythm* 2011;8:368-72.
[PUBMED](#) | [CROSSREF](#)
56. Di Biase L, Saenz LC, Burkhardt DJ, et al. Esophageal capsule endoscopy after radiofrequency catheter ablation for atrial fibrillation: documented higher risk of luminal esophageal damage with general anesthesia as compared with conscious sedation. *Circ Arrhythm Electrophysiol* 2009;2:108-12.
[PUBMED](#) | [CROSSREF](#)
57. Pires LA, Huang SK, Wagshal AB, Kulkarni RS. Electrophysiological effects of propofol on the normal cardiac conduction system. *Cardiology* 1996;87:319-24.
[PUBMED](#) | [CROSSREF](#)
58. Niksch A, Liberman L, Clapcich A, Schwarzenberger JC, Silver ES, Pass RH. Effects of remifentanyl anesthesia on cardiac electrophysiologic properties in children undergoing catheter ablation of supraventricular tachycardia. *Pediatr Cardiol* 2010;31:1079-82.
[PUBMED](#) | [CROSSREF](#)
59. Khan ZP, Ferguson CN, Jones RM. alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. *Anaesthesia* 1999;54:146-65.
[PUBMED](#) | [CROSSREF](#)
60. Lau W, Kovoov P, Ross DL. Cardiac electrophysiologic effects of midazolam combined with fentanyl. *Am J Cardiol* 1993;72:177-82.
[PUBMED](#) | [CROSSREF](#)
61. Harrison SJ, Mayet J. Physician administered sedation for DC cardioversion. *Heart* 2002;88:117-8.
[PUBMED](#) | [CROSSREF](#)
62. Lewis SR, Nicholson A, Reed SS, Kenth JJ, Alderson P, Smith AF. Anaesthetic and sedative agents used for electrical cardioversion. *Cochrane Database Syst Rev* 2015:CD010824.
[PUBMED](#) | [CROSSREF](#)
63. Kalogridaki M, Souvatzis X, Mavrakis HE, et al. Anaesthesia for cardioversion: a prospective randomised comparison of propofol and etomidate combined with fentanyl. *Hellenic J Cardiol* 2011;52:483-8.
[PUBMED](#)
64. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. *Circ Res* 2015;116:1509-26.
[PUBMED](#) | [CROSSREF](#)
65. Trentman TL, Fassett SL, Mueller JT, Altemose GT. Airway interventions in the cardiac electrophysiology laboratory: a retrospective review. *J Cardiothorac Vasc Anesth* 2009;23:841-5.
[PUBMED](#) | [CROSSREF](#)
66. Park JH, Soh S, Kwak YL, Kim B, Choi S, Shim JK. Anesthetic efficacy of dexmedetomidine versus midazolam when combined with remifentanyl for percutaneous transluminal angioplasty in patients with peripheral artery disease. *J Clin Med* 2019;8:E472.
[PUBMED](#) | [CROSSREF](#)